Halozyme Therapeutics Inc

2026-09-23 20:07; UTC

Halozyme Therapeutics Inc shares fell sharply after reaching a 52-week high, facing volatility and a decline during Wednesday's trading session.

2026-09-22 20:02; UTC

Halozyme Therapeutics Inc shares are rising as the company announced a $1.05 billion offering of convertible senior notes to enhance financial flexibility.

2026-09-21 20:06; UTC

Halozyme Therapeutics Inc shares fell as the company announced a proposed offering of $1.05 billion in convertible senior notes to extend debt maturity.

2026-09-18 20:06; UTC

Halozyme Therapeutics priced an upsized $1.3 billion offering of convertible senior notes, with shares trading higher amid strong session momentum.

2026-09-17 20:07; UTC

Halozyme Therapeutics announced a $1.05 billion convertible senior notes offering due in 2033, with shares trading higher amid strong performance metrics.

2026-09-16 23:01; UTC

Halozyme Therapeutics announced a proposed $1.05 billion offering of convertible senior notes, contributing to a decline in after-market trading.

2026-09-15 22:06; UTC

Halozyme Therapeutics Inc. shares were near unchanged in after-market hours, trading within a narrow range and below their 20-day moving average.

2026-09-09 20:07; UTC

Halozyme Therapeutics Inc is declining during Wednesday's session, continuing a trend lower since Tuesday. The stock remains above its 20-day moving average.

2026-09-08 19:26; UTC

Halozyme Therapeutics is trading lower, reflecting weakness after reaching a session high earlier. The stock remains down since Friday's close.

2026-09-02 20:08; UTC

HC Wainwright reiterated its Buy rating on Halozyme Therapeutics, maintaining a $115 price target as shares trade higher amid upcoming investor conference participation.

2026-09-01 20:08; UTC

Halozyme Therapeutics is rising today, driven by broader strength in biotechnology stocks. The stock remains near the upper end of its one-month range.

2026-08-28 20:08; UTC

Halozyme Therapeutics Inc shares declined Friday, reversing earlier gains amid rising U.S. Treasury yields and inflation concerns, with no specific news identified.

2026-08-27 19:16; UTC

Shares of Halozyme Therapeutics are lower during Thursday's session, reaching a low earlier. The stock remains above its 20-day moving average.

2026-08-26 23:46; UTC

Halozyme Therapeutics Inc. shares are higher in after-market trading, continuing gains since Wednesday's close and showing a strong month-over-month performance.

2026-08-25 19:36; UTC

Halozyme Therapeutics Inc is gaining during Tuesday's session, despite earlier trading lower. Broader market sentiment remains positive amid declining crude oil prices.

2026-08-24 23:36; UTC

Halozyme Therapeutics Inc shares are lower in after-market hours. Broader market concerns over geopolitical tensions are impacting investor confidence.

2026-08-21 19:36; UTC

Halozyme Therapeutics Inc is trading higher, continuing its upward trend since Thursday's close. No specific news was identified to explain the movement.

2026-08-20 20:06; UTC

Halozyme Therapeutics shares are lower amid concerns over recent insider selling by CEO Helen Torley, who sold $2.13 million in stock.

2026-08-19 19:56; UTC

Halozyme Therapeutics shares are higher as investor confidence grows following the election of Dannielle Appelhans to its Board of Directors.

2026-08-18 23:41; UTC

Halozyme shares are lower in after-market trading following the announcement of Dannielle Appelhans' election to the Board of Directors, effective August 2026.

2026-08-17 23:02; UTC

Halozyme Therapeutics shares are higher in after-market hours, recovering from earlier session declines and remaining near the upper end of their one-month trading range.

2026-08-14 20:06; UTC

Halozyme Therapeutics Inc shares are lower amid broader market concerns following a decline in U.S. retail sales, continuing a trend of volatility.

2026-08-13 19:56; UTC

Halozyme Therapeutics Inc shares are lower during Thursday's session, having retraced from an earlier peak with no specific news to explain the decline.

2026-08-12 19:16; UTC

Halozyme Therapeutics Inc shares are lower, pressured by a high Relative Strength Index indicating potential overbought conditions amid recent market sentiment.

2026-08-11 20:02; UTC

Halozyme Therapeutics reported strong second-quarter earnings, raising full-year revenue guidance to $1.87 billion. Shares are trading roughly flat amid high trading volume.

2026-08-10 22:36; UTC

Halozyme Therapeutics shares are higher in after-market trading, reaching a high above the 20-day moving average and near the upper end of its one-month range.

2026-08-07 23:21; UTC

Halozyme Therapeutics reported strong Q2 earnings and raised guidance, yet shares are trading lower in after-market hours following notable weakness.

2026-08-06 23:51; UTC

Halozyme Therapeutics shares advanced in after-market trading following record second-quarter results, with revenue rising to $481 million and guidance increased for the year.

2026-08-05 22:16; UTC

Halozyme Therapeutics shares are lower in after-market trading, reflecting broader market pressures amid mixed sentiment from geopolitical developments and weak employment data.

2026-08-04 19:22; UTC

Halozyme Therapeutics is higher today, driven by 39.1% revenue growth from its ENHANZE technology, which enhances market share and earnings performance.